Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 13,610 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Sleep
Interventions: GO! To Sleep, Sleep information, Blood Draw, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), SF-12 quality of life survey; Behavioral · Procedure · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma
Interventions: BMS-982470 (recombinant interleukin-21), Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more

Conditions: Psoriasis, Inflammation
Interventions: Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acne Vulgaris
Interventions: Winlevi (clascoterone) 1% cream; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Breast Cancer Female, Leptomeningeal Metastases
Interventions: HER2 BATs; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Locally Recurrent and Metastatic Breast Cancer
Interventions: AMG 386 Placebo, AMG 386, Bevacizumab, Paclitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Melanoma
Interventions: Trametinib daily Until PD, CDX-3379 (ERBB3 antibody); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Counseling session, Questionnaire 1, Questionnaire 2, online questionnaire; Behavioral · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years to 120 Years · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: aldesleukin, cytokine therapy, sargramostim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: St. Luke's Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions: CBX-12; Drug
Lead sponsor: Cybrexa Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more

Conditions: Breast Cancer
Interventions: Pain Coping Skills Training (PCST); Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 55 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Androgenetic Alopecia
Interventions: Fractionated Thulium laser; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Eczema, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: TopMD Skin Care, Inc.; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Interventions: INCB 99280 with Ipilimumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: Breast Cancer
Interventions: Paclitaxel, Cyclophosphamide, Carboplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 70 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Milford, Massachusetts + 2 more

Conditions: Breast Cancer
Interventions: Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Metastases
Interventions: anti-CEA CAR-T cells, Sir-Spheres; Biological · Device
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Systemic Sclerosis, Diffuse Scleroderma
Interventions: Privigen; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Ad-RTS-hIL-12, Veledimex; Biological · Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2065
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
Interventions: Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram; Diagnostic Test · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions: Testosterone; Drug
Lead sponsor: Creighton University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Biological Therapy in Treating Women With Metastatic Breast Cancer

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Behavioral Pain Intervention for Older Cancer Patients

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

'ADVANCE' (A Pilot Trial)

Selective Image Guided Resection of Axillary Lymph Nodes

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

IVIG Treatment in Systemic Sclerosis

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

RASopathy Biorepository

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy